Device/Diagnostics Quarterly Dealmaking Statistics, Q4 2018
A look at the financing, M&A and alliance activity in October–December 2018
Device fundraising in the fourth quarter totaled $1.5bn, a 42% decrease from Q3's $2.6bn. Q4 M&A activity reached $8.6bn. Q4 diagnostics financings brought in $1.2bn (a 32% increase over Q3) and M&As totaled $1.3bn (the second-highest quarter of the year).
You may also be interested in...
Boston Scientific has acquired the remaining shares of privately held mitral-valve repair device company Millipede for $325m.
When Boston Scientific chief medical officer Ian Meredith spoke in mid-2018 of the group's appetite for core M&A, there was a sense that more strategic moves were likely before the year was out. The inference was right, and a busy year for Boston Scientific got much busier when it made a cash offer for UK interventional medicine specialist BTG PLC. The bid values the target company at $4.28 billion, and completion is expected by mid-2019.
Stryker is continuing its buying spree with the purchase of HyperBranch Medical Technology. The orthopedics giant announced it will pay $220m in an all-cash deal to buy the maker of Adherus, a hydrogel that helps dural repair.